Loading…
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $256M | $-161M | $-103M | $12M | -28.4% | 23.3% | -44.8% |
| 2024 | $208M | $-203M | $-187M | $-165M | -44.4% | -4.2% | -559.5% |
| 2023 | $217M | $-172M | $41M | $-150M | 7.4% | 19.7% | -127.3% |
| 2022 | $181M | $-142M | $-149M | $-128M | -33.3% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 180.96 | 216.67 | 207.54 | 255.87 |
| Operating Revenue | - | 180.96 | 216.67 | 207.54 | 255.87 |
| Cost Of Revenue | - | 79.93 | 75.97 | 75.46 | 113.26 |
| Gross Profit | - | 101.02 | 140.69 | 132.08 | 142.61 |
| Operating Expense | - | 247.84 | 318.14 | 341.38 | 309.51 |
| Research And Development | - | 126.37 | 181.77 | 201.78 | 173.14 |
| Selling General And Administration | - | 121.47 | 136.37 | 139.59 | 136.37 |
| Total Expenses | - | 327.77 | 394.11 | 416.84 | 422.76 |
| Operating Income | - | -146.82 | -177.45 | -209.30 | -166.90 |
| Total Operating Income As Reported | - | -146.82 | -177.45 | -209.30 | -166.90 |
| EBITDA | - | -142.47 | -171.90 | -203.14 | -160.87 |
| Normalized EBITDA | - | -124.39 | -225.36 | -208.82 | -209.05 |
| EBIT | - | -146.82 | -177.45 | -209.30 | -166.90 |
| Interest Income | 1.06 | - | - | - | - |
| Net Interest Income | 1.06 | - | - | - | - |
| Other Non Operating Income Expenses | - | 3.95 | 19.69 | 17.90 | 16.40 |
| Other Income Expense | - | -2.31 | 220.37 | 23.58 | 64.57 |
| Interest Income Non Operating | 1.06 | - | - | - | - |
| Net Non Operating Interest Income Expense | 1.06 | - | - | - | - |
| Pretax Income | - | -149.12 | 42.92 | -185.71 | -102.33 |
| Tax Provision | - | 0.06 | 2.20 | 1.41 | 0.94 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -3.80 | 2.73 | 1.19 | 10.12 |
| Net Income Continuous Operations | - | -149.19 | 40.72 | -187.12 | -103.26 |
| Net Income From Continuing And Discontinued Operation | - | -149.19 | 40.72 | -187.12 | -103.26 |
| Net Income From Continuing Operation Net Minority Interest | - | -149.19 | 40.72 | -187.12 | -103.26 |
| Net Income | - | -149.19 | 40.72 | -187.12 | -103.26 |
| Net Income Common Stockholders | - | -149.19 | 40.72 | -187.12 | -103.26 |
| Net Income Including Noncontrolling Interests | - | -149.19 | 40.72 | -187.12 | -103.26 |
| Normalized Income | - | -134.90 | -10.01 | -191.61 | -141.32 |
| Diluted NI Availto Com Stockholders | - | -149.19 | 40.72 | -187.12 | -103.26 |
| Basic Average Shares | - | 71.17 | 71.78 | 72.67 | 73.44 |
| Diluted Average Shares | - | 71.17 | 74.99 | 72.67 | 73.44 |
| Reconciled Depreciation | - | 4.34 | 5.55 | 6.16 | 6.02 |
| Reconciled Cost Of Revenue | - | 79.93 | 75.97 | 75.46 | 113.26 |
| Total Unusual Items | - | -18.08 | 53.46 | 5.68 | 48.17 |
| Total Unusual Items Excluding Goodwill | - | -18.08 | 53.46 | 5.68 | 48.17 |
| Minority Interests | 0.83 | 0 | 0 | - | - |
| Gain On Sale Of Security | - | -18.08 | 53.46 | 5.68 | 48.17 |
| General And Administrative Expense | - | 90.82 | 99.15 | 99.68 | 95.41 |
| Other Gand A | - | 90.82 | 99.15 | 99.68 | 95.41 |
| Selling And Marketing Expense | - | 30.64 | 37.23 | 39.92 | 40.96 |
| Earnings From Equity Interest | - | 11.82 | 147.21 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Schrödinger, Inc.this co. | SDGR | $1.2B | -11.47 | 3.25 | -28.4% | -6.61 |
| Inspire Medical Systems, Inc. | INSP | $1.2B | 8.36 | 1.56 | 18.6% | 14.32 |
| IRADIMED CORPORATION | IRMD | $1.2B | 53.21 | 12.64 | 23.8% | 41.92 |
| CareDx, Inc. | CDNA | $1.2B | -55.93 | 3.94 | -7.0% | -248.15 |
| Kestra Medical Technologies, Ltd. | KMTS | $1.2B | -10.49 |
| - |
| - |
| - |
| - |
| - |
| 5.81 |
| -55.4% |
| -10.21 |
| AMN Healthcare Services, Inc. | AMN | $1.2B | - | 1.85 | -14.9% | 19.35 |
| Wave Life Sciences Ltd. | WVE | $1.2B | - | 2.26 | -39.4% | - |
| Avanos Medical, Inc. | AVNS | $1.2B | - | 1.50 | -9.4% | - |
| Zenas BioPharma, Inc. | ZBIO | $1.2B | -3.07 | 4.79 | -156.0% | -2.84 |
| Peer Median | - | -3.07 | 3.10 | -12.1% | 5.74 | |